Charles Lapp: Difference between revisions
m (Text replacement - "Talks & interviews" to "Talks and interviews") |
Notjusttired (talk | contribs) m (Text replacement - "author-link8 = | last8" to "author-link7 = | last8") |
||
(229 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
[[File:Dr. Charles Lapp.png|right|Source: Hunter-Hopkins Center]] | [[File:Dr. Charles Lapp.png|right|Source: Hunter-Hopkins Center]] | ||
'''Charles W. Lapp''', MD, is a retired Internal Medicine physician and the Medical Director Emeritus at [[Hunter-Hopkins Center]] in Charlotte, North Carolina, [[United States|US]], which has a practice specializing in [[ME/CFS]], [[FM]], and related conditions | '''Charles W. Lapp''', MD, is a retired Internal Medicine physician and the Medical Director Emeritus at [[Hunter-Hopkins Center]] in Charlotte, North Carolina, [[United States|US]], which has a practice specializing in [[ME/CFS]], [[FM|fibromyalgia]], and related conditions.<ref>{{Cite web | url = https://drlapp.com/staff/curriculum-vitae-charles-w-lapp-md/ | title = Curriculum Vitae – Charles W. Lapp, MD | last = | first = | authorlink = | date = | website = Hunter-Hopkins Center|language=en-US| archive-url = | archive-date = |url-status = | access-date=2020-10-26}}</ref> Earlier in his career, he practiced family medicine and pediatrics in Raleigh, NC.<ref name="retirement"/> He became interested in [[ME/CFS]] following an outbreak of three small epidemics of a chronic fatiguing illness in the Raleigh area. [[1984 Chapel Hill outbreak|One of these outbreaks]] was among all the members of the N.C. Symphony Orchestra.<ref>{{Cite web | url = http://newsok.com/article/3366622 | title = Cause of illness remains unknown | last = Garloch | first = Karen | date = 2009 | website = NewsOK| archive-url = | archive-date = |url-status = | access-date= | authorlink = }}</ref> | ||
From 1992 to 1995 Dr. Lapp acted as Medical Director of the Cheney Clinic in Charlotte, in collaboration with Dr. [[Paul Cheney]]. In August 1995, Dr. Lapp opened the Hunter-Hopkins Center in Charlotte, North Carolina where he practiced until his retirement in 2018.<ref name=" | From 1992 to 1995 Dr. Lapp acted as Medical Director of the Cheney Clinic in Charlotte, in collaboration with Dr. [[Paul Cheney]]. In August 1995, Dr. Lapp opened the [[Hunter-Hopkins Center]] in Charlotte, North Carolina where he practiced until his retirement in 2018.<ref name="retirement" /> His center does testing for disability insurance such as the [[two-day cardiopulmonary exercise test]] (2-day CPET) and a computer-assisted cognitive function test. | ||
Following Dr. Lapp's retirement in 2018, the Hunter-Hopkins Center director became Dr. [[Vincent Hillman|Vincent F. Hillman]] with Dr. [[Laura Black]] continuing on staff.<ref name=": | Following Dr. Lapp's retirement in 2018, the Hunter-Hopkins Center director became Dr. [[Vincent Hillman|Vincent F. Hillman]] with Dr. [[Laura Black]] continuing on staff.<ref name="retirement">{{Cite web | url = https://drlapp.com/news/me-letter-february-2018/#retires | title = Dr. Lapp Retires and Dr. Vincent Hillman Takes the Helm | date = 2018-02-12|language=en-US|access-date=2018-12-23 | website = Hunter-Hopkins Center | last = Lapp | first = Charles | authorlink = Charles Lapp|archive-url=|archive-date=|url-status=}}</ref> | ||
Dr. Lapp serves on the editorial board of the journal, [[Fatigue: Biomedicine, Health & Behavior]], published on behalf of the [[IACFS/ME]].<ref>{{Cite web | url = https://www.tandfonline.com/action/journalInformation?show=editorialBoard&journalCode=rftg20& | title = Fatigue: Biomedicine, Health & Behavior | website = tandfonline.com|access-date=2019-11-01}}</ref> | |||
==Awards== | ==Awards== | ||
*2009, Nelson Gantz Outstanding Clinician Award awarded to a physician who emulates Nelson Gantz's clinical acumen, his passion for medicine, and his empathy for persons with CFS/FM awarded by [[International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis | *2009, Nelson Gantz Outstanding Clinician Award awarded to a physician who emulates Nelson Gantz's clinical acumen, his passion for medicine, and his empathy for persons with CFS/FM awarded by [[International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis]].<ref>{{Cite web | url = https://www.iacfsme.org/iacfs-me-awardees | title = IACFS/ME Awardees | website = | ||
IACFS/ME|access-date=2020-04-23}}</ref> | |||
==IOM Committee on Diagnostic Criteria for ME/CFS== | ==IOM Committee on Diagnostic Criteria for ME/CFS== | ||
Dr Lapp was a reviewer for the [[Institute of Medicine report|2015 report]] produced by the [[Institute of Medicine]]'s Committee on Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.<ref>{{Cite web|url=https://www.nap.edu/resource/19012/MECFS_Powerpoint.pdf|title=ME/CFS Presentation|last=Institute of Medicine|first=|authorlink=Institute of Medicine | Dr Lapp was a reviewer for the [[Institute of Medicine report|2015 report]] produced by the [[Institute of Medicine]]'s Committee on Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.<ref>{{Cite web | url = https://www.nap.edu/resource/19012/MECFS_Powerpoint.pdf | title=ME/CFS Presentation | last = Institute of Medicine | first = | authorlink = Institute of Medicine | date = | website = National Academies Press| archive-url = | archive-date = |url-status = | access-date=2018-12-23}}</ref> | ||
==Pediatric Case Definition== | ==Pediatric Case Definition== | ||
Line 18: | Line 21: | ||
==Clinical Trials== | ==Clinical Trials== | ||
The [[Hunter-Hopkins Center]] was one of two clinical sites participating in the [[Hemispherx Biopharma]] 511/open label [[Ampligen]] trials to gain [[FDA]] approval, which was ultimately unsuccessful. The [[Ampligen]] phase III trial results were published in 2012.<ref name="Strayer, 2012" /><ref name=":0">{{Cite web|url=https://drlapp.com/research/#tabs_6431815605c1f658582e55-tab_2|title=Ampligen {{!}} Research {{!}} Hunter-Hopkins Center, P.A.|last=Hunter-Hopkins Center|first=|authorlink=Hunter-Hopkins Center | The [[Hunter-Hopkins Center]] was one of two clinical sites participating in the [[Hemispherx Biopharma]] 511/open label [[Ampligen]] trials to gain [[FDA]] approval, which was ultimately unsuccessful. The [[Ampligen]] phase III trial results were published in 2012.<ref name="Strayer, 2012" /><ref name=":0">{{Cite web | url = https://drlapp.com/research/#tabs_6431815605c1f658582e55-tab_2 | title = Ampligen {{!}} Research {{!}} Hunter-Hopkins Center, P.A. | last = Hunter-Hopkins Center | first = | authorlink = Hunter-Hopkins Center | date = | website = |language=en-US| archive-url = | archive-date = |url-status = | access-date=2018-12-23}}</ref> Ampligen, a brand name for '''Rintatolimod''', is an IV medication, and was given twice weekly at the Hunter-Hopkins infusion room during the trial. The Hunter-Hopkins Center is currently one of four clinics that can administer Ampligen in the US.<ref name=":0" /> | ||
==Clinic location== | ==Clinic location== | ||
Dr Lapp retired in 2018, other physicians with expertise in ME/CFS can be contacted at the clinic he founded. | |||
:Hunter-Hopkins Center | :Hunter-Hopkins Center | ||
Line 28: | Line 33: | ||
:Email: drlapp@drlapp.net | :Email: drlapp@drlapp.net | ||
==Notable | ==Notable studies== | ||
*1997, Management of Chronic Fatigue Syndrome in Children: A Practicing Clinician's Approach<ref>Charles W. Lapp. (1997). Management of Chronic Fatigue Syndrome in Children: A Practicing Clinician's Approach. ''Journal of Chronic Fatigue Syndrome,'' Vol. 3, Iss. 2, pp 59-76. http://dx.doi.org/10.1300/J092v03n02_07</ref> | *1997, Management of Chronic Fatigue Syndrome in Children: A Practicing Clinician's Approach<ref>Charles W. Lapp. (1997). Management of Chronic Fatigue Syndrome in Children: A Practicing Clinician's Approach. ''Journal of Chronic Fatigue Syndrome,'' Vol. 3, Iss. 2, pp 59-76. http://dx.doi.org/10.1300/J092v03n02_07</ref> | ||
Line 37: | Line 42: | ||
*2009, Severe versus Moderate criteria for the new [[pediatric]] case definition for [[ME/CFS]]<ref name="Jason, Dec2009" /> [https://www.ncbi.nlm.nih.gov/pubmed/19513826 (Abstract)] | *2009, Severe versus Moderate criteria for the new [[pediatric]] case definition for [[ME/CFS]]<ref name="Jason, Dec2009" /> [https://www.ncbi.nlm.nih.gov/pubmed/19513826 (Abstract)] | ||
*2012, A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist [[rintatolimod]] in severe cases of chronic fatigue syndrome<ref name="Strayer, 2012" /> [http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0031334 (Full Text)] | *2012, A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist [[rintatolimod]] in severe cases of chronic fatigue syndrome<ref name="Strayer, 2012" /> [http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0031334 (Full Text)] | ||
*2014, No association found between the detection of either [[xenotropic murine leukemia virus-related virus]] or polytropic murine leukemia virus and [[chronic fatigue syndrome]] in a blinded, multi-site, prospective study by the establishment and use of the [[SolveCFS BioBank & Patient Registry|SolveCFS BioBank]]<ref>{{Cite journal|last=Irlbeck|first=David M.|last2=Vernon|first2=Suzanne D.|author-link2=Suzanne Vernon|last3=McCleary|first3=K. Kimberly|author-link3=Kim McCleary|last4=Bateman|first4=Lucinda|author-link4=Lucinda Bateman|last5=Klimas|first5=Nancy G.|author-link5=Nancy Klimas|last6=Lapp|first6=Charles W.|author-link6=Charles Lapp|last7=Peterson|first7=Daniel L.|author-link7=Daniel Peterson|last8=Brown|first8=James R.|last9=Remlinger|first9=Katja S.|date=2014|title=No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236736/|journal=BMC Research Notes|volume=7|pages=461|doi=10.1186/1756-0500-7-461|via=|last10=Wilfret|last11=Gerondelis|first11=Peter|first10=David A.}}</ref> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236736/ (Full Text)] | *2014, No association found between the detection of either [[xenotropic murine leukemia virus-related virus]] or polytropic murine leukemia virus and [[chronic fatigue syndrome]] in a blinded, multi-site, prospective study by the establishment and use of the [[SolveCFS BioBank & Patient Registry|SolveCFS BioBank]]<ref>{{Cite journal | last = Irlbeck | first = David M. | last2 = Vernon | first2 = Suzanne D. | author-link2 = Suzanne Vernon | last3 = McCleary | first3 = K. Kimberly | author-link3 = Kim McCleary | last4 = Bateman | first4 = Lucinda | author-link4 = Lucinda Bateman | last5 = Klimas | first5 = Nancy G. | author-link5 = Nancy Klimas | last6 = Lapp | first6 = Charles W. | author-link6 = Charles Lapp | last7 = Peterson | first7 = Daniel L. | author-link7 = Daniel Peterson | last8 = Brown | first8 = James R. | last9 = Remlinger | first9 = Katja S.| date = 2014 | title = No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank | url =https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236736/ | journal = BMC Research Notes | volume = 7 | pages = 461|doi=10.1186/1756-0500-7-461|via= | last10 = Wilfret | last11 = Gerondelis | first11 = Peter | first10 = David A.}}</ref> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236736/ (Full Text)] | ||
*2016, [[CDC]] Grand Rounds: [[Chronic Fatigue Syndrome]] — Advancing Research and Clinical Education. Morbidity and [[Mortality]] Weekly Report<ref>{{Cite journal|last1=Unger|first1=ER| | *2016, [[CDC]] Grand Rounds: [[Chronic Fatigue Syndrome]] — Advancing Research and Clinical Education. Morbidity and [[Mortality]] Weekly Report<ref>{{Cite journal | last1 = Unger | first1 = ER | authorlink = Elizabeth Unger | last2 = Lin | first2 = JS | author-link2 = Jin-Mann Sally Lin | last3 = Brimmer | first3 = DJ | author-link3 = | last4 = Lapp | first4 = CW | author-link4 = Charles Lapp | last5 = Komaroff | first5 = AL | author-link5 = Anthony Komaroff | last6 = Nath | first6 = A | author-link6 = Avindra Nath | last7 = Laird | first7 = S | author-link7 = | last8 = Iskander | first8 = J | author-link8 = John Iskander | title = CDC Grand Rounds: Chronic Fatigue Syndrome — Advancing Research and Clinical Education | journal = Morbidity and Mortality Weekly Report | volume = 65 | issue = 5051| page=1434–1438 | date = 2016 | doi=10.15585/mmwr.mm655051a4}} - </ref> - [https://www.cdc.gov/mmwr/volumes/65/wr/mm655051a4.htm (Full Text)] | ||
*2017, Multi-Site Clinical Assessment of [[ME/CFS|Myalgic Encephalomyelitis/Chronic Fatigue Syndrome]] (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study<ref name="Unger, 2017" /> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565838/ (Full Text)] | *2017, Multi-Site Clinical Assessment of [[ME/CFS|Myalgic Encephalomyelitis/Chronic Fatigue Syndrome]] (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study<ref name="Unger, 2017" /> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565838/ (Full Text)] | ||
*2019, Initiating care of a patient with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)<ref>{{Cite journal|last=Lapp|first=Charles W.| | *2019, Initiating care of a patient with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)<ref>{{Cite journal | last = Lapp | first = Charles W. | authorlink = Charles Lapp | date = Jan 2019 | title = Initiating Care Of A Patient With Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) | url = https://www.frontiersin.org/articles/10.3389/fped.2018.00415/abstract | journal = Frontiers in Pediatrics | volume = | issue = | pages = |doi=10.3389/fped.2018.00415|quote=|via=}}</ref> [https://www.frontiersin.org/articles/10.3389/fped.2018.00415/full (Full text)] | ||
*2019, Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning<ref>{{Cite journal|last=Proskauer|first=Charmian| | *2019, Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning<ref>{{Cite journal | last = Proskauer | first = Charmian | authorlink = Charmian Proskauer | last2 = Rowe | first2 = Peter C. | author-link2 = Peter Rowe | last3 = Lapp | first3 = Charles W. | author-link3 = Charles Lapp | last4 = DeMaria | first4 = Alfred Jr | author-link4 = | last5 = Bateman | first5 = Lucinda | author-link5 = Lucinda Bateman | last6 = Attewell | first6 = John R. | last7 = Proskauer | first7 = Daniel | last8 = Kiernicki | first8 = David J. | last9 = Adebayo | first9 = Seyi | date = 2019 | title=Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning | url =https://www.frontiersin.org/articles/10.3389/fped.2018.00412/full | journal = Frontiers in Pediatrics|language=English | volume = 6 | issue = | pages = |doi=10.3389/fped.2018.00412|issn=2296-2360|pmc=|pmid=30671425|quote=|via=}}</ref> [https://www.frontiersin.org/articles/10.3389/fped.2018.00412/full (Full text)] | ||
==Talks and interviews== | ==Talks and interviews== | ||
*[http://www.cfidsselfhelp.org/library/dr-lapp's-recommedations-supplements Dr. Lapp’s recommendations on supplements]<ref>{{Cite web|url=http://www.cfidsselfhelp.org/library/dr-lapp%27s-recommedations-supplements|title=Dr Lapp's Recommendations on Supplements {{!}} ME/CFS & Fibromyalgia Self-Help|last=Campbell|first=Bruce|authorlink=Bruce Campbell | *[http://www.cfidsselfhelp.org/library/dr-lapp's-recommedations-supplements Dr. Lapp’s recommendations on supplements]<ref>{{Cite web | url = http://www.cfidsselfhelp.org/library/dr-lapp%27s-recommedations-supplements | title = Dr Lapp's Recommendations on Supplements {{!}} ME/CFS & Fibromyalgia Self-Help | last = Campbell | first = Bruce | authorlink = Bruce Campbell | date = | website = cfidsselfhelp.org| archive-url = | archive-date = |url-status = | access-date=2018-12-23}}</ref> | ||
*16 Feb 2016, CDC Grand Rounds - Chronic Fatigue Syndrome: Advancing Research and Clinical Education with Charles Lapp, MD, [[Elizabeth Unger]], PhD, MD, [[Anthony Komaroff]], MD and [[Avindra Nath]], MD | *16 Feb 2016, CDC Grand Rounds - Chronic Fatigue Syndrome: Advancing Research and Clinical Education with Charles Lapp, MD, [[Elizabeth Unger]], PhD, MD, [[Anthony Komaroff]], MD and [[Avindra Nath]], MD | ||
Line 58: | Line 63: | ||
==Open Letter to ''The Lancet''== | ==Open Letter to ''The Lancet''== | ||
Three open letters to the editor of ''The Lancet'' urged the editor to commission a fully independent review of the [[PACE trial]], which the journal had published in 2011. In 2016, Dr. Lapp, along with 42 colleagues in the [[ME/CFS]] field, signed the second letter.<ref>{{Cite web|url=http://www.virology.ws/2016/02/10/open-letter-lancet-again/|title=Open Letter Lancet Again|last=|first=|date=|website=|archive-url=|archive-date=| | Three open letters to the editor of ''The Lancet'' urged the editor to commission a fully independent review of the [[PACE trial]], which the journal had published in 2011. In 2016, Dr. Lapp, along with 42 colleagues in the [[ME/CFS]] field, signed the second letter.<ref>{{Cite web | url = http://www.virology.ws/2016/02/10/open-letter-lancet-again/ | title = Open Letter Lancet Again | last = | first = | date = | website = | archive-url = | archive-date = |url-status = | access-date=}}</ref> In 2018, Dr. Lapp, with more than 100 colleagues in the [[ME/CFS]] field, signed the third letter.<ref>{{Cite web | url = http://www.virology.ws/2018/06/19/trial-by-error-an-open-letter-to-the-lancet-two-years-on/ | title = An Open Letter to The Lancet, Two Years On | last = | first = | date = | website = | archive-url = | archive-date = |url-status = | access-date=}}</ref> | ||
*10 February 2016, [http://www.virology.ws/2016/02/10/open-letter-lancet-again/ An open letter to The Lancet, again - Virology blog] | *10 February 2016, [http://www.virology.ws/2016/02/10/open-letter-lancet-again/ An open letter to The Lancet, again - Virology blog] | ||
Line 73: | Line 78: | ||
*2012, [http://drlapp.com/ask-the-doctor/what-are-the-most-important-things-to-remember-about-cfs-fm/ What Are The Most Important Things To Remember About CFS/FM?] | *2012, [http://drlapp.com/ask-the-doctor/what-are-the-most-important-things-to-remember-about-cfs-fm/ What Are The Most Important Things To Remember About CFS/FM?] | ||
*[http://drlapp.com/staff/curriculum-vitae-charles-w-lapp-md/ Curriculum Vitae - Charles W. Lapp, MD] | *[http://drlapp.com/staff/curriculum-vitae-charles-w-lapp-md/ Curriculum Vitae - Charles W. Lapp, MD] | ||
*2018, [https://www.healthrising.org/blog/2018/03/28/lapp-chronic-fatigue-syndrome-fibromyalgia-pioneer-retires/ An ME/CFS and FM Pioneer Says Good-bye: The Charles Lapp Interview]<ref>{{Cite web|url=https://www.healthrising.org/blog/2018/03/28/lapp-chronic-fatigue-syndrome-fibromyalgia-pioneer-retires/|title=An ME/CFS and FM Pioneer Says Good-bye: The Charles Lapp Interview|last=Johnson|first=Cort|authorlink=Cort Johnson | *2018, [https://www.healthrising.org/blog/2018/03/28/lapp-chronic-fatigue-syndrome-fibromyalgia-pioneer-retires/ An ME/CFS and FM Pioneer Says Good-bye: The Charles Lapp Interview]<ref>{{Cite web | url = https://www.healthrising.org/blog/2018/03/28/lapp-chronic-fatigue-syndrome-fibromyalgia-pioneer-retires/ | title = An ME/CFS and FM Pioneer Says Good-bye: The Charles Lapp Interview | last = Johnson | first = Cort | authorlink = Cort Johnson | date = 2018-03-28 | website = [[Health Rising]]|language=en-GB| archive-url = | archive-date = |url-status = | access-date=2018-12-23}}</ref> | ||
==See also== | ==See also== | ||
*[[Hunter-Hopkins Center]] | |||
*[[NIH Post-Infectious ME/CFS Study]] | *[[NIH Post-Infectious ME/CFS Study]] | ||
*[[Ampligen]] | *[[Ampligen]] | ||
*[[1984 Chapel Hill outbreak]] | *[[1984 Chapel Hill outbreak]] | ||
*Dr. [[Laura Black]] | *Dr [[Vincent Hillman|Vincent F. Hillman]] | ||
*Dr [[Laura Black]] | |||
==References== | ==References== | ||
<references> | <references> | ||
<ref name="Jason, Dec2009">{{Citation | <ref name="Jason, Dec2009">{{Citation | last = Jason | first1 = Leonard | author-link1 = Leonard Jason | last2 = Porter | first2 = Nicole | author-link2 = Nicole Porter | last3 = Shelleby | first3 = E | author-link3 = | last4 = Till | first4 = L | author-link4 = | last5 = Bell | first5 = David S | author-link5 = David Bell | last6 = Lapp | first6 = Charles W | author-link6 = Charles Lapp | last7 =Rowe | first7 = Kathy | author-link8 = Kathy Rowe | last8 = De Meirleir | first8 = Kenny | author-link8 = Kenny De Meirleir | title = Severe versus Moderate criteria for the new pediatric case definition for ME/CFS | journal = Child Psychiatry and Human Development | volume = 40 | issue = 4 | page = 609-20 | date = 2009 | pmid = | doi = 10.1007/s10578-009-0147-8 }}</ref> | ||
| | <ref name="JasonL2006paed">{{citation | last = Jason | first1 = Leonard A | author-link1 = Leonard Jason | last2 = Jordan | first2 = Karen | author-link2 = Karen Jordan | last3 = Miike | first3 = Teruhisa | author-link3 = Teruhisa Miike | last4 = Bell | first4 = David S | author-link4 = David Bell | last5 = Lapp | first5 = Charles| author-link5 = Charles Lapp | last6 = Torres-Harding | first6 = Susan | author-link6 = Susan Torres-Harding | last7 =Rowe | first7 = Kathy | author-link8 = Kathy Rowe | last8 = Gurwitt | first8 = Alan | author-link8 = Alan Gurwitt | last9 = De Meirleir | first9 = Kenny | author-link9 = Kenny de Meirleir | last10 = Van Hoof | first10 = Elke LS | author-link10 = Elke Van Hoof | title = A Pediatric Case Definition for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome | journal = Journal of Chronic Fatigue Syndrome | volume = 13 | issue = 2-3 | pages = 1-44 | date = 2006 | doi = 10.1300/J092v13n02_01 | url = https://solvecfs.org/wp-content/uploads/2013/06/pediatriccasedefinitionshort.pdf }}</ref> | ||
| last2 | <ref name="Strayer, 2012">{{Citation | last =Strayer | first1 = DR | author-link1 = David Strayer | last2 = Carter | first2 = WA | author-link2 = William Carter | last3 = Stouch | first3 = BC | author-link3 = | last4 = Stevens | first4 = SR | author-link4 = Staci Stevens | last5 = Bateman | first5 = L | author-link5 = Lucinda Bateman | last6 = Cimoch | first6 = PJ | author-link6 = | last7 =Lapp | first7 = CW | author-link8 = Charles Lapp | last8 = Peterson | first8 = DL | author-link8 = Daniel Peterson | last9 = Chronic Fatigue Syndrome AMP-516 Study Group | author-link9 = | last10 = Mitchell | first10 = WM | author-link10 = William Mitchell | title = A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. | journal = PLoS One | volume = 7 | issue = 3 | page = e31334 | date = 2012 | pmid = 22431963 | doi = 10.1371/journal.pone.0031334 }}</ref> | ||
| last3 | <ref name="Unger, 2017">{{Citation | last =Unger | first1 = Elizabeth R. | author-link1 = Elizabeth Unger | last2 = Lin | first2 = Jin-Mann S. | author-link2 = Jin-Mann Sally Lin | last3 = Tian | first3 = Hao | author-link3 = | last4 = Natelson | first4 = Benjamin H. | author-link4 = Benjamin Natelson | last5 = Lange | first5 = Gudrun | author-link5 = Gudrun Lange | last6 = Vu | first6 = Diana | author-link6 = | last7 =Blate | first7 = Michelle | author-link7 = | last8 = Klimas | first8 = Nancy G. | author-link8 = Nancy Klimas | last9 = Balbin | first9 = Elizabeth G. | author-link9 = | last10 = Bateman | first10 = Lucinda | author-link10 = Lucinda Bateman | last11 = Allen | first11 = Ali | author-link11 = | last12 = Lapp | first12 = Charles W. | author-link12 = Charles Lapp | last13 = Springs | first13 = Wendy | author-link13 = | last14 = Kogelnik | first14 = Andreas M. | author-link14 = Andreas Kogelnik | last15 = Phan | first15 = Catrina C. | author-link15 = | last16 = Danver | first16 = Joan | author-link16 = | last17 = Podell | first17 = Richard N. | author-link17 = Richard Podell | last18 = Fitzpatrick | first18 = Trisha | author-link18 = | last19 = Peterson | first19 = Daniel L. | author-link19 = Daniel Peterson | last20 = Gottschalk | first20 = C. Gunnar| author-link20 = Gunnar Gottschalk | last21 = Rajeevan | first21 = Mangalathu S. | author-link21 = Mangalathu Rajeevan | last22 = MCAM Study Group | title = Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study. | journal = American Journal of Epidemiology | volume = 1-10 | issue = | page = | date = 2017 | pmid = | doi = 10.1093/aje/kwx029 }}</ref> | ||
| last4 | <ref name="Van Hoof, 2007">{{Citation | last =Van Hoof | first1 = E | author-link1 = Elke Van Hoof | last2 = De Becker | first2 = P | author-link2 = Pascale De Becker | last3 = Lapp | first3 = C | author-link3 = Charles Lapp | last4 = Cluydts | first4 = R | author-link4 = | last5 = De Meirleir | first5 = K | author-link5 = Kenny de Meirleir | title = Defining the Occurrence and Influence of Alpha-Delta Sleep in Chronic Fatigue Syndrome | journal = The American Journal of the Medical Sciences | volume = 333 | issue = 2 | page = 78-84 | date = 2007 | pmid = 17301585 | doi = }}</ref> | ||
| last5 | <ref name="Vojdani, 1998">{{Citation | last =Vojdani | first1 = A | author-link1 = | last2 = Choppa | first2 = PC | author-link2 = | last3 = Lapp | first3 = CW | author-link3 = Charles Lapp | title = Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome | journal = J Clin Lab Immunol | volume = 50 | issue = 1 | page = 1-16 | date = 1998 | pmid = 10189612 | doi = }}</ref> | ||
| last6 | |||
| last7 | |||
| last8 | |||
| title | |||
| journal = Child Psychiatry and Human Development | |||
| date | |||
| pmid | |||
| doi | |||
}} | |||
</ref> | |||
<ref name="JasonL2006paed">{{citation | |||
| | |||
| last2 | |||
| last3 | |||
| last4 | |||
| last5 | |||
| last6 | |||
| last7 | |||
| last8 | |||
| last9 | |||
| last10 | |||
| title | |||
| journal = Journal of Chronic Fatigue Syndrome | volume = 13 | issue = 2-3 | | |||
| date | |||
| doi | |||
| url | |||
}}</ref> | |||
<ref name="Strayer, 2012">{{Citation | |||
| | |||
| last2 | |||
| last3 | |||
| last4 | |||
| last5 | |||
| last6 | |||
| last7 | |||
| last8 | |||
| last9 | |||
| last10 | |||
| title | |||
| journal = PLoS One | |||
| date | |||
| pmid | |||
| doi | |||
}} | |||
</ref> | |||
<ref name="Unger, 2017">{{Citation | |||
| | |||
| last2 | |||
| last3 | |||
| last4 | |||
| last5 | |||
| last6 | |||
| last7 | |||
| last8 | |||
| last9 | |||
| last10 | |||
| last11 | |||
| last12 | |||
| last13 | |||
| last14 | |||
| last15 | |||
| last16 | |||
| last17 | |||
| last18 | |||
| last19 | |||
| last20 | |||
| last21 | |||
| last22 | |||
| title | |||
| journal = American Journal of Epidemiology | volume = 1-10 | issue = | |||
| date | |||
| pmid | |||
| doi | |||
}} | |||
</ref> | |||
<ref name="Van Hoof, 2007">{{Citation | |||
| | |||
| last2 | |||
| last3 | |||
| last4 | |||
| last5 | |||
| title | |||
| journal = The American Journal of the Medical Sciences | volume = 333 | |||
| date | |||
| pmid | |||
| doi | |||
}} | |||
</ref> | |||
<ref name="Vojdani, 1998">{{Citation | |||
| | |||
| last2 | |||
| last3 | |||
| title | |||
| journal = J Clin Lab Immunol | |||
| date | |||
| pmid | |||
| doi | |||
}} | |||
</ref> | |||
</references> | </references> | ||
Latest revision as of 19:57, July 29, 2023
Charles W. Lapp, MD, is a retired Internal Medicine physician and the Medical Director Emeritus at Hunter-Hopkins Center in Charlotte, North Carolina, US, which has a practice specializing in ME/CFS, fibromyalgia, and related conditions.[1] Earlier in his career, he practiced family medicine and pediatrics in Raleigh, NC.[2] He became interested in ME/CFS following an outbreak of three small epidemics of a chronic fatiguing illness in the Raleigh area. One of these outbreaks was among all the members of the N.C. Symphony Orchestra.[3]
From 1992 to 1995 Dr. Lapp acted as Medical Director of the Cheney Clinic in Charlotte, in collaboration with Dr. Paul Cheney. In August 1995, Dr. Lapp opened the Hunter-Hopkins Center in Charlotte, North Carolina where he practiced until his retirement in 2018.[2] His center does testing for disability insurance such as the two-day cardiopulmonary exercise test (2-day CPET) and a computer-assisted cognitive function test.
Following Dr. Lapp's retirement in 2018, the Hunter-Hopkins Center director became Dr. Vincent F. Hillman with Dr. Laura Black continuing on staff.[2]
Dr. Lapp serves on the editorial board of the journal, Fatigue: Biomedicine, Health & Behavior, published on behalf of the IACFS/ME.[4]
Awards[edit | edit source]
- 2009, Nelson Gantz Outstanding Clinician Award awarded to a physician who emulates Nelson Gantz's clinical acumen, his passion for medicine, and his empathy for persons with CFS/FM awarded by International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.[5]
IOM Committee on Diagnostic Criteria for ME/CFS[edit | edit source]
Dr Lapp was a reviewer for the 2015 report produced by the Institute of Medicine's Committee on Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.[6]
Pediatric Case Definition[edit | edit source]
- 2006, A Pediatric Case Definition for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome[7] (Full Text)
Clinical Trials[edit | edit source]
The Hunter-Hopkins Center was one of two clinical sites participating in the Hemispherx Biopharma 511/open label Ampligen trials to gain FDA approval, which was ultimately unsuccessful. The Ampligen phase III trial results were published in 2012.[8][9] Ampligen, a brand name for Rintatolimod, is an IV medication, and was given twice weekly at the Hunter-Hopkins infusion room during the trial. The Hunter-Hopkins Center is currently one of four clinics that can administer Ampligen in the US.[9]
Clinic location[edit | edit source]
Dr Lapp retired in 2018, other physicians with expertise in ME/CFS can be contacted at the clinic he founded.
- Hunter-Hopkins Center
- 7421 Carmel Executive Park Dr.
- Charlotte, North Carolina 28226
- Telephone: (704) 543-9692
- Email: drlapp@drlapp.net
Notable studies[edit | edit source]
- 1997, Management of Chronic Fatigue Syndrome in Children: A Practicing Clinician's Approach[10]
- 1998, Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome.[11]
- 1999, The Relationship Between Chronic Fatigue Syndrome and Chemical Exposure[12]
- 2006, Recognizing Pediatric CFS in the Primary Care Practice: A Practicing Clinician's Approach[13]
- 2007, Defining the Occurrence and Influence of Alpha-Delta Sleep in Chronic Fatigue Syndrome[14] (Abstract)
- 2009, Severe versus Moderate criteria for the new pediatric case definition for ME/CFS[15] (Abstract)
- 2012, A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome[8] (Full Text)
- 2014, No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank[16] (Full Text)
- 2016, CDC Grand Rounds: Chronic Fatigue Syndrome — Advancing Research and Clinical Education. Morbidity and Mortality Weekly Report[17] - (Full Text)
- 2017, Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study[18] (Full Text)
- 2019, Initiating care of a patient with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)[19] (Full text)
- 2019, Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning[20] (Full text)
Talks and interviews[edit | edit source]
- Dr. Lapp’s recommendations on supplements[21]
- 16 Feb 2016, CDC Grand Rounds - Chronic Fatigue Syndrome: Advancing Research and Clinical Education with Charles Lapp, MD, Elizabeth Unger, PhD, MD, Anthony Komaroff, MD and Avindra Nath, MD
HHS/CFSAC Testimony[edit | edit source]
Open Letter to The Lancet[edit | edit source]
Three open letters to the editor of The Lancet urged the editor to commission a fully independent review of the PACE trial, which the journal had published in 2011. In 2016, Dr. Lapp, along with 42 colleagues in the ME/CFS field, signed the second letter.[22] In 2018, Dr. Lapp, with more than 100 colleagues in the ME/CFS field, signed the third letter.[23]
- 10 February 2016, An open letter to The Lancet, again - Virology blog
- 18 June 2018, Trial By Error: An Open Letter to The Lancet, Two Years On
Online presence[edit | edit source]
Learn more[edit | edit source]
- 2012, What Are The Most Important Things To Remember About CFS/FM?
- Curriculum Vitae - Charles W. Lapp, MD
- 2018, An ME/CFS and FM Pioneer Says Good-bye: The Charles Lapp Interview[24]
See also[edit | edit source]
- Hunter-Hopkins Center
- NIH Post-Infectious ME/CFS Study
- Ampligen
- 1984 Chapel Hill outbreak
- Dr Vincent F. Hillman
- Dr Laura Black
References[edit | edit source]
- ↑ "Curriculum Vitae – Charles W. Lapp, MD". Hunter-Hopkins Center. Retrieved October 26, 2020.
- ↑ 2.0 2.1 2.2 Lapp, Charles (February 12, 2018). "Dr. Lapp Retires and Dr. Vincent Hillman Takes the Helm". Hunter-Hopkins Center. Retrieved December 23, 2018.
- ↑ Garloch, Karen (2009). "Cause of illness remains unknown". NewsOK.
- ↑ "Fatigue: Biomedicine, Health & Behavior". tandfonline.com. Retrieved November 1, 2019.
- ↑ "IACFS/ME Awardees". IACFS/ME. Retrieved April 23, 2020.
- ↑ Institute of Medicine. "ME/CFS Presentation" (PDF). National Academies Press. Retrieved December 23, 2018.
- ↑ Jason, Leonard A; Jordan, Karen; Miike, Teruhisa; Bell, David S; Lapp, Charles; Torres-Harding, Susan; Rowe, Kathy; Gurwitt, Alan; De Meirleir, Kenny; Van Hoof, Elke LS (2006), "A Pediatric Case Definition for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome" (PDF), Journal of Chronic Fatigue Syndrome, 13 (2–3): 1–44, doi:10.1300/J092v13n02_01
- ↑ 8.0 8.1 Strayer, DR; Carter, WA; Stouch, BC; Stevens, SR; Bateman, L; Cimoch, PJ; Lapp, CW; Peterson, DL; Chronic Fatigue Syndrome AMP-516 Study Group; Mitchell, WM (2012), "A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.", PLoS One, 7 (3): e31334, doi:10.1371/journal.pone.0031334, PMID 22431963
- ↑ 9.0 9.1 Hunter-Hopkins Center. "Ampligen | Research | Hunter-Hopkins Center, P.A." Retrieved December 23, 2018.
- ↑ Charles W. Lapp. (1997). Management of Chronic Fatigue Syndrome in Children: A Practicing Clinician's Approach. Journal of Chronic Fatigue Syndrome, Vol. 3, Iss. 2, pp 59-76. http://dx.doi.org/10.1300/J092v03n02_07
- ↑ Vojdani, A; Choppa, PC; Lapp, CW (1998), "Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome", J Clin Lab Immunol, 50 (1): 1-16, PMID 10189612
- ↑ Aristo Vojdani & Charles W. Lapp. (1999). The Relationship Between Chronic Fatigue Syndrome and Chemical Exposure. Journal of Chronic Fatigue Syndrome, Vol. 5, Iss. 3-4, pp. 207-221. http://dx.doi.org/10.1300/J092v05n03_18
- ↑ Charles W. Lapp. (2006). Recognizing Pediatric CFS in the Primary Care Practice: A Practicing Clinician's Approach. Journal of Chronic Fatigue Syndrome, Vol. 13, Iss. 2-3, pp. 89-96. http://dx.doi.org/10.1300/J092v13n02_06
- ↑ Van Hoof, E; De Becker, P; Lapp, C; Cluydts, R; De Meirleir, K (2007), "Defining the Occurrence and Influence of Alpha-Delta Sleep in Chronic Fatigue Syndrome", The American Journal of the Medical Sciences, 333 (2): 78-84, PMID 17301585
- ↑ Jason, Leonard; Porter, Nicole; Shelleby, E; Till, L; Bell, David S; Lapp, Charles W; Rowe, Kathy; De Meirleir, Kenny (2009), "Severe versus Moderate criteria for the new pediatric case definition for ME/CFS", Child Psychiatry and Human Development, 40 (4): 609-20, doi:10.1007/s10578-009-0147-8
- ↑ Irlbeck, David M.; Vernon, Suzanne D.; McCleary, K. Kimberly; Bateman, Lucinda; Klimas, Nancy G.; Lapp, Charles W.; Peterson, Daniel L.; Brown, James R.; Remlinger, Katja S.; Wilfret, David A.; Gerondelis, Peter (2014). "No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank". BMC Research Notes. 7: 461. doi:10.1186/1756-0500-7-461.
- ↑ Unger, ER; Lin, JS; Brimmer, DJ; Lapp, CW; Komaroff, AL; Nath, A; Laird, S; Iskander, J (2016). "CDC Grand Rounds: Chronic Fatigue Syndrome — Advancing Research and Clinical Education". Morbidity and Mortality Weekly Report. 65 (5051): 1434–1438. doi:10.15585/mmwr.mm655051a4. -
- ↑ Unger, Elizabeth R.; Lin, Jin-Mann S.; Tian, Hao; Natelson, Benjamin H.; Lange, Gudrun; Vu, Diana; Blate, Michelle; Klimas, Nancy G.; Balbin, Elizabeth G.; Bateman, Lucinda; Allen, Ali; Lapp, Charles W.; Springs, Wendy; Kogelnik, Andreas M.; Phan, Catrina C.; Danver, Joan; Podell, Richard N.; Fitzpatrick, Trisha; Peterson, Daniel L.; Gottschalk, C. Gunnar; Rajeevan, Mangalathu S.; MCAM Study Group (2017), "Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study.", American Journal of Epidemiology, 1–10, doi:10.1093/aje/kwx029
- ↑ Lapp, Charles W. (January 2019). "Initiating Care Of A Patient With Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS)". Frontiers in Pediatrics. doi:10.3389/fped.2018.00415.
- ↑ Proskauer, Charmian; Rowe, Peter C.; Lapp, Charles W.; DeMaria, Alfred Jr; Bateman, Lucinda; Attewell, John R.; Proskauer, Daniel; Kiernicki, David J.; Adebayo, Seyi (2019). "Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning". Frontiers in Pediatrics. 6. doi:10.3389/fped.2018.00412. ISSN 2296-2360. PMID 30671425.
- ↑ Campbell, Bruce. "Dr Lapp's Recommendations on Supplements | ME/CFS & Fibromyalgia Self-Help". cfidsselfhelp.org. Retrieved December 23, 2018.
- ↑ "Open Letter Lancet Again".
- ↑ "An Open Letter to The Lancet, Two Years On".
- ↑ Johnson, Cort (March 28, 2018). "An ME/CFS and FM Pioneer Says Good-bye: The Charles Lapp Interview". Health Rising. Retrieved December 23, 2018.